Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies

European Journal of Internal Medicine

Volumn 25, Issue 5, 2014, Pages 482-484

  Biondo, M I ^a   Germano, V ^a   Pietrosanti, M ^a   Canzoni, M ^a   Marignani, M ^a   Stroffolini, T ^b   Salemi, S ^a   D'Amelio, R ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNF ; HBcAb positive; HBV reactivation; Rheumatic diseases

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA; ANTIRHEUMATIC AGENT; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; VIRUS REACTIVATION; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD; CHRONIC DISEASE; DRUG EFFECTS; HETEROZYGOTE; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; VIRUS ACTIVATION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARRIER STATE; CHRONIC DISEASE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84901638809     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.11.014     Document Type: Article

References (24)

1. D.E. Furst The risk of infections with biologic therapies for rheumatoid arthritis Semin Arthritis Rheum 39 2010 327 346
2. A. Marzano, E. Angelucci, P. Andreone, M. Brunetto, R. Bruno, and P. Burra et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients Dig Liver Dis 39 2007 397 408
3. D.M. Nathan, P.W. Angus, and P.R. Gibson Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach J Gastroenterol Hepatol 21 2006 1366 1371
4. G. Raimondo, T. Pollicino, I. Cacciola, and G. Squadrito Occult hepatitis B virus infection J Hepatol 46 2007 160 170
5. M. Viganò, E. Degasperi, A. Aghemo, P. Lampertico, and M. Colombo Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management Expert Opin Biol Ther 12 2012 193 207
6. R. Pérez-Alvarez, C. Díaz-Lagares, F. García- Hernández, L. Lopez-Roses, P. Brito-Zerón, and M. Pérez-de-Lis et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine (Baltimore) 90 2011 359 371
7. S. Mori Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs Mod Rheumatol 21 2011 621 627
8. Y. Urata, R. Uesato, D. Tanaka, K. Kowatari, T. Nitobe, and Y. Nakamura et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients Mod Rheumatol 21 2011 16 23
9. R. Caporali, F. Bobbio-Pallavicini, F. Atzeni, G. Sakellariou, M. Caprioli, and C. Montecucco et al. Safety tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases Arthritis Care Res 62 2010 749 754
10. C. Charpin, S. Guis, P. Colson, P. Borentain, J.P. Mattéi, and P. Alcaraz et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients Arthritis Res Ther 11 2009 R179
11. F.C. Arnett, S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, and N.S. Cooper et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 1988 315 324
12. S. Van der Linden, H.A. Valkenburg, and A. Cats Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis Rheum 27 1984 361 368
13. J.M. Moll, and V. Wright Psoriatic arthritis Semin Arthritis Rheum 3 1973 55 78
14. D.M. Van der Heijde, M.A. Van't Hof, P.L. Van Riel, L.A. Theunisse, E.W. Lubberts, and M.A. Van Leeuwen et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score Ann Rheum Dis 49 1990 916 920
15. S. Garrett, T. Jenkinson, L.G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index J Rheumatol 21 1994 2286 2291
16. M. Marignani, E. Gigante, P. Begini, A. Marzano, M. di Fonzo, and I. Deli et al. Patients with hematological malignancies and serological signs of prior resolved hepatitis B World J Gastrointest Oncol 4 2012 37 45
17. Y.J. Kim, S.C. Bae, Y.K. Sung, T.H. Kim, J.B. Jun, and D.H. Yoo et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases J Rheumatol 37 2010 346 350
18. D. Vassilopoulos, A. Apostolopoulou, E. Hadziyannis, G.V. Papatheodoridis, S. Manolakopoulos, and J. Koskinas et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection Ann Rheum Dis 69 2010 1352 1355
19. J.L. Lan, Y.M. Chen, T.Y. Hsieh, Y.H. Chen, C.W. Hsieh, and D.Y. Chen et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Ann Rheum Dis 70 2011 1719 1725
20. R.A. Pondé Atypical serological profiles in hepatitis B virus infection Eur J Clin Microbiol Infect Dis 32 2012 461 476
21. M. Kato, T. Atsumi, T. Kurita, T. Odani, Y. Fujieda, and K. Otomo et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases J Rheumatol 38 2011 2209 2214
22. Y.H. Lee, S.C. Bae, and G.G. Song Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy Clin Exp Rheumatol 31 2013 118 121
23. M. Marignani, M. Canzoni, R. D'Amelio, E. De Santis, A. Pecchioli, and G. Delle Fave Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO Eur J Intern Med 22 2011 576 581
24. A.L. Cheng, C.A. Hsiung, I.J. Su, P.J. Chen, M.C. Chang, and C.J. Tsao et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Hepatology 37 2003 1320 1328